发布求助
文献互助 智能选刊 最新文献

Leukemia Research Reports最新文献

筛选
英文 中文
Case report: A young woman with acute peri‑myocarditis and acute myeloid leukaemia with myelodysplasia-related changes 病例报告：一名年轻女性急性心肌炎和急性髓性白血病伴骨髓增生异常相关改变
IF 0.7
Leukemia Research Reports Pub Date : 2025-01-01 DOI: 10.1016/j.lrr.2025.100527
Zsolt Szakács , Tamás Habon , László Kereskai , László Gopcsa , Hussain Alizadeh
{"title":"Case report: A young woman with acute peri‑myocarditis and acute myeloid leukaemia with myelodysplasia-related changes","authors":"Zsolt Szakács ,&nbsp;Tamás Habon ,&nbsp;László Kereskai ,&nbsp;László Gopcsa ,&nbsp;Hussain Alizadeh","doi":"10.1016/j.lrr.2025.100527","DOIUrl":"10.1016/j.lrr.2025.100527","url":null,"abstract":"<div><h3>Background</h3><div>Clinical presentation in acute myeloid leukaemia (AML) can result in a wide variety of clinical phenotypes.</div></div><div><h3>Case Report</h3><div>We report the case of a 34-year-old woman who presented with severe peri‑myocarditis and concomitant AML. The patient was treated with 5-azacitidine and venetoclax followed by haploidentical allogenic haematopoetic stem cell transplantation. Unfortunately, the patient developed febrile neutropenia and died because of overwhelming neutropenic sepsis. On autopsy, no evidence of AML was identified neither in bone marrow nor in cardiac tissue.</div></div><div><h3>Conclusion</h3><div>With this case report, we would like to emphasize the possibility of cardiac involvement in AML as well as the potential application of novel therapeutic agents in AML patients unfit for intensive chemotherapy.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"24 ","pages":"Article 100527"},"PeriodicalIF":0.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144654380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of non-coding RNAs on resistance to imatinib in chronic myelogenous leukemia 非编码rna对慢性粒细胞白血病伊马替尼耐药的影响
IF 0.7
Leukemia Research Reports Pub Date : 2025-01-01 DOI: 10.1016/j.lrr.2025.100529
Fatemeh Ensafi Talemi , Soudeh Ghafouri-Fard
{"title":"Impact of non-coding RNAs on resistance to imatinib in chronic myelogenous leukemia","authors":"Fatemeh Ensafi Talemi ,&nbsp;Soudeh Ghafouri-Fard","doi":"10.1016/j.lrr.2025.100529","DOIUrl":"10.1016/j.lrr.2025.100529","url":null,"abstract":"<div><div>Imatinib is approved as the first-line treatment for newly diagnosed chronic myelogenous leukemia (CML). In spite of profound response in the majority of patients, resistance occurs in a subgroup of CML cases. Recently, it has been demonstrated that different classes of non-coding RNAs can modulate response to this tyrosine kinase inhibitor. Recognition of the role of these transcripts in this process not only expands our knowledge about the molecular mechanisms of imatinib resistance, but also provides novel strategies for combating this phenotype. The current review summarizes the role of non-coding RNAs in this process and suggests novel candidates for further studies in this field to enhance therapeutic response to imatinib.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"24 ","pages":"Article 100529"},"PeriodicalIF":0.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144605228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comprehensive analysis of Atypical chronic myeloid leukemia (aCML): Epidemiology, clinical features, and survival outcomes based on SEER database insights 非典型慢性髓性白血病（aCML）的综合分析：基于SEER数据库见解的流行病学，临床特征和生存结果
IF 0.7
Leukemia Research Reports Pub Date : 2025-01-01 DOI: 10.1016/j.lrr.2025.100505
Zhaoyang Hong , Fan Wang
{"title":"Comprehensive analysis of Atypical chronic myeloid leukemia (aCML): Epidemiology, clinical features, and survival outcomes based on SEER database insights","authors":"Zhaoyang Hong ,&nbsp;Fan Wang","doi":"10.1016/j.lrr.2025.100505","DOIUrl":"10.1016/j.lrr.2025.100505","url":null,"abstract":"<div><h3>Background</h3><div>Atypical Chronic Myeloid Leukemia (aCML) is a rare and aggressive myelodysplastic syndrome/myeloproliferative neoplasm. This study aimed to provide a comprehensive understanding of the epidemiology, clinical characteristics, and survival outcomes of aCML patients.</div></div><div><h3>Methods</h3><div>The study utilized data from the Surveillance, Epidemiology, and End Results (SEER) database from 2001 to 2020. The age-adjusted incidence rate (AIR) of aCML was calculated, and survival outcomes were analyzed using the Kaplan-Meier method and accelerated failure time (AFT) regression analysis.</div></div><div><h3>Results</h3><div>The AIR of aCML was found to be 0.024 per 100,000 person-years, with the highest rate observed in 2020. The incidence of aCML increased with age and was higher in males. The study cohort predominantly consisted of elderly White individuals, with an average age at diagnosis of 68.2 ± 15.3 years. The median overall survival (OS) and disease-specific survival (DSS) were 1.4 years and 1.7 years, respectively. Older age was independently associated with worse survival outcomes. Notably, treatment delay and chemotherapy did not significantly impact OS or DSS.</div></div><div><h3>Conclusions</h3><div>This study provides comprehensive insights into the epidemiology, clinical characteristics, and survival outcomes of aCML, highlighting its rarity, aggressive nature, and poor prognosis. Further research is needed to validate these findings and explore novel therapeutic strategies for improving outcomes in this challenging hematologic malignancy.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"23 ","pages":"Article 100505"},"PeriodicalIF":0.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143437342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
First reported TRIB1 copy number loss in myelodysplastic syndrome (MDS) revealed by single nucleotide polymorphism array (SNP-array) with patient-matched control 首次报道的TRIB1拷贝数丢失在骨髓增生异常综合征（MDS）中发现，单核苷酸多态性阵列（SNP-array）与患者匹配的对照
IF 0.9
Leukemia Research Reports Pub Date : 2025-01-01 DOI: 10.1016/j.lrr.2025.100542
Kun Chi , Lili Song
{"title":"First reported TRIB1 copy number loss in myelodysplastic syndrome (MDS) revealed by single nucleotide polymorphism array (SNP-array) with patient-matched control","authors":"Kun Chi ,&nbsp;Lili Song","doi":"10.1016/j.lrr.2025.100542","DOIUrl":"10.1016/j.lrr.2025.100542","url":null,"abstract":"<div><div>A 30-year-old woman with MDS with low blasts (MDS-LB) presented a somatic 67-kb copy number loss at 8q24.13 involving <em>TRIB1</em>, detected by single nucleotide polymorphism (SNP) array. Bone marrow analysis showed no mutations in common MDS genes (<em>TP53, ASXL1, TET2, RUNX1</em>) or karyotypic abnormalities (46, XX). Using oral epithelial DNA as a patient-matched control, SNP-array identified four hereditary uniparental disomies (UPDs) and a somatic <em>TRIB1</em>-containing deletion at 8q24.13. This deletion likely caused <em>TRIB1</em> haploinsufficiency, reducing control over dysplastic clones and driving progression to MDS with increased blasts 2 (MDS-IB2) over three years. This first report of <em>TRIB1</em> copy number loss in myeloid disorders highlights the value of SNP-array with patient-matched controls in distinguishing somatic variants, expanding MDS’s genetic profile and underscoring <em>TRIB1</em>’s context-dependent roles in oncogenesis.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"24 ","pages":"Article 100542"},"PeriodicalIF":0.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144932327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A rare case of CD38-negative abdominal multiple extramedullary plasmacytoma and literature review cd38阴性腹腔多发髓外浆细胞瘤1例并文献复习。
IF 0.7
Leukemia Research Reports Pub Date : 2025-01-01 DOI: 10.1016/j.lrr.2024.100493
XS Bao, DH Gong, KG Zhou, W Huang
{"title":"A rare case of CD38-negative abdominal multiple extramedullary plasmacytoma and literature review","authors":"XS Bao,&nbsp;DH Gong,&nbsp;KG Zhou,&nbsp;W Huang","doi":"10.1016/j.lrr.2024.100493","DOIUrl":"10.1016/j.lrr.2024.100493","url":null,"abstract":"<div><div>Abdominal multiple extramedullary plasmacytoma (EMP) is a rare disease. CD38-negative relapsed/refractory EMP after treatment with daratumumab has never been reported. In 2020, a patient with jaundice was diagnosed with plasmacytoma in another hospital, which progressed one year after receiving multiline therapy. In July 2021, he was admitted to our hospital and showed CD38-pogative plasmacytoma. The patient received 2 cycles of treatment including daratumumab, venetoclax and DCEP chemotherapy and achieved partial remission. However, he developed ascites and eventually died. Our case indicated that multiple EMP has much lower incidence and far worse prognosis than solitary EMP.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"23 ","pages":"Article 100493"},"PeriodicalIF":0.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11731487/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142984853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tyrosine kinase inhibitors modulate the expression of peroxiredoxins 1 and 2 in chronic myeloid leukemia cells 酪氨酸激酶抑制剂调节慢性髓性白血病细胞中过氧化物还毒素1和2的表达
IF 0.7
Leukemia Research Reports Pub Date : 2025-01-01 DOI: 10.1016/j.lrr.2025.100508
Hiroshi Kazama , Yan-Hua Wang , Junji Tanaka
{"title":"Tyrosine kinase inhibitors modulate the expression of peroxiredoxins 1 and 2 in chronic myeloid leukemia cells","authors":"Hiroshi Kazama ,&nbsp;Yan-Hua Wang ,&nbsp;Junji Tanaka","doi":"10.1016/j.lrr.2025.100508","DOIUrl":"10.1016/j.lrr.2025.100508","url":null,"abstract":"<div><div>Chronic myeloid leukemia (CML) is characterized by the presence of the BCR::ABL1 fusion protein with active tyrosine kinase activity. The BCR::ABL1 fusion protein induces the production of reactive oxygen species (ROS). DNA damage caused by ROS is involved in the mechanism of CML progression. Antioxidant systems include peroxiredoxins (PRDXs), which play various roles in hematological malignancies. Although tyrosine kinase inhibitors (TKIs) are known to affect ROS production, their effects on the expression of the antioxidants PRDX1 and PRDX2 remain unclear; thus, we aimed to evaluate the effects of TKIs on the expression of these PRDXs and ROS levels in CML cells. We found that TKIs, such as imatinib, nilotinib, and dasatinib, increased the gene expression of <em>PRDX2</em> in K562 cells; however, only dasatinib increased the cytoplasmic protein expression of PRDX2. Additionally, while TKIs reduced the gene expression of <em>PRDX1</em> in contrast to that of <em>PRDX2</em>, dasatinib increased the cytoplasmic protein expression of PRDX1. This discrepancy was linked to post-translational regulation through SUMOylation in cooperation with dasatinib. Our results suggest that the antioxidants PRDX1 and PRDX2 could serve as potential targets for TKIs in the treatment of CML.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"23 ","pages":"Article 100508"},"PeriodicalIF":0.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143685842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Management of Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia in a Jehovah’s Witness using chemotherapy free regimen: A case report and review of literature ​
IF 0.7
Leukemia Research Reports Pub Date : 2025-01-01 DOI: 10.1016/j.lrr.2025.100517
Muhammad Hassan Raza , Eiraj Khan , Alexis M Desjarlais , Salman Fazal
{"title":"Management of Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia in a Jehovah’s Witness using chemotherapy free regimen: A case report and review of literature","authors":"Muhammad Hassan Raza ,&nbsp;Eiraj Khan ,&nbsp;Alexis M Desjarlais ,&nbsp;Salman Fazal","doi":"10.1016/j.lrr.2025.100517","DOIUrl":"10.1016/j.lrr.2025.100517","url":null,"abstract":"<div><h3>Introduction and Importance</h3><div>Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (pH-positive ALL) in Jehovah’s Witness (JW) using chemotherapy agents, opens an ethically and morally challenging paradigm instead of their religious practices.</div></div><div><h3>Case Presentation</h3><div>We present a case of pH-positive B cell ALL in a Jehovah's Witness patient who refused the transfusion of blood as a part of their treatment regimen. We intended to treat this patient using a new “chemotherapy-free” approach and achieved Minimal Residual Disease (MRD) negative state with durable outcomes for the next three years.</div></div><div><h3>Clinical Discussion</h3><div>With “chemotherapy-free” regimen, we achieved complete molecular remission without any significant side effects in our patient.</div></div><div><h3>Conclusion</h3><div>Chemo-free approach is a promising opportunity to treat Jehovah’s witnesses with pH-positive B cell ALL as the haemoglobin and platelets remained above transfusion thresholds. However, further research is required to fully understand and implement this approach. Future clinical trials should consider including this unique patient population to better understand their needs and improve outcomes.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"24 ","pages":"Article 100517"},"PeriodicalIF":0.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144306787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diagnostic and taxonomic challenges in chronic myelomonocytic leukemia with lymph node involvement: A case report and mini-review 慢性髓细胞白血病伴淋巴结累及的诊断和分类学挑战：一例报告和小型回顾
IF 0.7
Leukemia Research Reports Pub Date : 2025-01-01 DOI: 10.1016/j.lrr.2025.100520
Bhaumik Shah , Mitra Abdollahi-Neisani , Pegah Taheri , Asya Varshavsky , Reza Nejati , Nicholas Mackrides
{"title":"Diagnostic and taxonomic challenges in chronic myelomonocytic leukemia with lymph node involvement: A case report and mini-review","authors":"Bhaumik Shah ,&nbsp;Mitra Abdollahi-Neisani ,&nbsp;Pegah Taheri ,&nbsp;Asya Varshavsky ,&nbsp;Reza Nejati ,&nbsp;Nicholas Mackrides","doi":"10.1016/j.lrr.2025.100520","DOIUrl":"10.1016/j.lrr.2025.100520","url":null,"abstract":"<div><div>The WHO and ICC classifications lack standardized terminology to define the disease phase of chronic myeloproliferative neoplasms in extramedullary sites, particularly lymph nodes, when infiltrates resemble extramedullary hematopoiesis (EH). We report a lymph node case of extramedullary chronic myelomonocytic leukemia (CMML) in blast phase mimicking EH. Comprehensive genomic profiling, using chromosomal microarray and NGS-based sequencing, identified copy neutral loss of heterozygosity (cn-LOH), previously unreported in extramedullary CMML. We discuss challenges in determining the CMML disease phase in lymph nodes and review the literature to underscore the need for consensus terminology for cases not meeting myeloid sarcoma criteria.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"24 ","pages":"Article 100520"},"PeriodicalIF":0.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144306833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Isolated bone marrow gamma/delta T-cell lymphoma: A difficult case to classify according to the current WHO classification of lymphoid malignancies 孤立骨髓γ / δ t细胞淋巴瘤：根据目前世界卫生组织对淋巴细胞恶性肿瘤的分类，这是一个难以分类的病例
IF 0.9
Leukemia Research Reports Pub Date : 2025-01-01 DOI: 10.1016/j.lrr.2025.100539
Hideto Hyuuga , Naoki Oishi , Takuma Kumagai , Minori Matuura , Ayato Nakadate , Yuma Sakamoto , Jun Suzuki , Megumi Suzuki , Megumi Koshiisi , Ichiro Kawashima , Takeo Yamamoto , Kei Nakajima , Masaru Tanaka , Tetuso Kondo , Keita Kirito
{"title":"Isolated bone marrow gamma/delta T-cell lymphoma: A difficult case to classify according to the current WHO classification of lymphoid malignancies","authors":"Hideto Hyuuga ,&nbsp;Naoki Oishi ,&nbsp;Takuma Kumagai ,&nbsp;Minori Matuura ,&nbsp;Ayato Nakadate ,&nbsp;Yuma Sakamoto ,&nbsp;Jun Suzuki ,&nbsp;Megumi Suzuki ,&nbsp;Megumi Koshiisi ,&nbsp;Ichiro Kawashima ,&nbsp;Takeo Yamamoto ,&nbsp;Kei Nakajima ,&nbsp;Masaru Tanaka ,&nbsp;Tetuso Kondo ,&nbsp;Keita Kirito","doi":"10.1016/j.lrr.2025.100539","DOIUrl":"10.1016/j.lrr.2025.100539","url":null,"abstract":"","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"24 ","pages":"Article 100539"},"PeriodicalIF":0.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144852637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Real-world management of blastic plasmacytoid dendritic cell neoplasm at an academic center with a broad regional referral base 在一个具有广泛区域转诊基础的学术中心，母浆细胞样树突状细胞肿瘤的实际管理
IF 0.9
Leukemia Research Reports Pub Date : 2025-01-01 DOI: 10.1016/j.lrr.2025.100541
Nathan M. Krah , Rasmus Hoeg , Paul J. Shami , Shannon E. Elf , Lauren E. Lee , Naveen Pemmaraju , Ami B. Patel
{"title":"Real-world management of blastic plasmacytoid dendritic cell neoplasm at an academic center with a broad regional referral base","authors":"Nathan M. Krah ,&nbsp;Rasmus Hoeg ,&nbsp;Paul J. Shami ,&nbsp;Shannon E. Elf ,&nbsp;Lauren E. Lee ,&nbsp;Naveen Pemmaraju ,&nbsp;Ami B. Patel","doi":"10.1016/j.lrr.2025.100541","DOIUrl":"10.1016/j.lrr.2025.100541","url":null,"abstract":"<div><div>BPDCN is an aggressive myeloid malignancy characterized by unique expression of CD123, CD4, CD56, CD303, CD304, TCL1 and TCF4. The development of tagraxofusp, a CD123-directed cytotoxin, has revolutionized BPDCN treatment, especially for patients unfit for chemotherapy. While most patients respond to frontline tagraxofusp, there are challenges associated with treatment. In this case series, we describe our institutional experience treating BPDCN both pre- and post-tagraxofusp approval. We summarize six cases, the majority of which occurred in elderly patients, and highlight unique challenges of treating BPDCN at a center that serves a large rural/frontier area with variable access to specialty care.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"24 ","pages":"Article 100541"},"PeriodicalIF":0.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144906947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信